Skip to content

The Impact of Serum Luteinizing Hormone Levels on Embryo Quality and Clinical Outcomes in a Fixed GnRH Antagonist Protocol: A Prospective, Observational Cohort Study

The Impact of Serum Luteinizing Hormone Levels on Embryo Quality and Clinical Outcomes in a Fixed GnRH Antagonist Protocol: A Prospective, Observational Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124805
Enrollment
Unknown
Registered
2026-05-18
Start date
2026-05-18
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Infertility observation group:None

Sponsors

Lishui People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
22 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients who meet all the inclusion criteria below can be included in this study: 1. Age >= 22 and < 40 years old; 2. Clinically diagnosed with infertility, with at least one indication for IVF/ICSI, and planned to receive an antagonist fixed protocol treatment based on goserelin acetate; 3. Have signed the informed consent form.

Exclusion criteria

Exclusion criteria: Any of the following conditions disqualifies an individual from being included in the study: 1. Patients with contraindications for assisted reproductive technology or pregnancy restrictions; 2. Any chromosomal abnormalities in either parent; 3. History of recurrent miscarriage; 4. Abnormalities in the uterus or fallopian tubes: presence of uterine abnormalities (unresolved endometrial fibroids, intrauterine adhesions, uterine malformations, etc.) or fallopian tube abnormalities (such as untreated tubal hydrosalpinx); 5. Ovarian pathology: existing ovarian pathological conditions; 6. Severe male infertility caused by male factors: including but not limited to: severe oligoasthenospermia (such as sperm concentration < 5×10^6/mL, or forward motile sperm percentage < 10%, or normal morphology rate < 1%); azoospermia (non-obstructive); the male is known to carry genetic diseases or chromosomal structural abnormalities (unless PGT-SR/PGT-M has been performed); 7. The male's semen sample cannot be obtained or the individual refuses to provide it (such as due to surgery, illness, or other reasons); 8. Missing core data collected retrospectively (LH test values).

Design outcomes

Primary

MeasureTime frame
Live birth rate per initiated cycle;

Secondary

MeasureTime frame
Day 3 and Day 5 embryo quality;Number of oocytes retrieved;Embryo implantation rate;Biochemical pregnancy rate;Clinical pregnancy rate;Cumulative live birth rate;Cycle cancellation rate;

Countries

China

Contacts

Public ContactWu Honglian

Lishui People's Hospital

19715787368@163.com+86 5772780764

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026